Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has announced positive Phase II data from two different interferon-free, Phase II studies for the treatment of hepatitis C (HCV).
Subscribe to our email newsletter
The Co-Pilot showed sustained virological response at 12 weeks post treatment (SVR12) in 95% and 93% of treatment-naïve genotype 1 (GT1) patients.
In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r.
The Pilot study showed 91% of genotype 1 infected, treatment-naïve patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).
Abbott infectious disease development divisional vice president Scott Brun said: "The data suggest that with a 12-week regimen containing just two of our direct-acting antiviral medicines, and no peginterferon, we can achieve high cure rates in treatment-naïve, genotype 1 patients."